Market Research Logo

Global Myelodysplastic Syndrome Market 2015-2019

Global Myelodysplastic Syndrome Market 2015-2019

About Myelodysplastic Syndrome

Myelodysplastic syndrome is a group of hematologic disorders that arise in the bone marrow and spread into the blood. The syndrome is characterized by the inability of the hematopoietic cells produced in the bone marrow to attain maturity. Cytological dysplasia is a common feature of the syndrome, progressing to acute myeloid leukemia in about 30% of individuals with myelodysplastic syndrome. The disease is age-related, mostly affecting people aged 60 and above. Smoking, exposure to radiation, contact with chemicals such as benzene, genetic mutations, and chemotherapy can cause myelodysplastic syndrome.

Technavio’s analysts forecast the global myelodysplastic syndrome market to grow at a CAGR of 9.93% during the period 2015-2019.

Covered in this report

The report covers the present scenario and the growth prospects of the global myelodysplastic syndrome market for 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used for treating myelodysplastic syndrome.

The report describes the market by region:

  • Americas: The US, Canada, Mexico, and Brazil
  • EMEA: The UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
  • APAC: Japan, China, Australia, Singapore, South Korea, and India
Technavio's report, Global Myelodysplastic Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Celgene
  • Novartis
  • Otsuka
Other prominent vendors
  • Acceleron Pharma
  • Amgen
  • Astellas
  • Astex
  • Actinium Pharmaceuticals
  • Bellicum Pharmaceuticals
  • BioLineRx
  • Celator Pharmaceuticals
  • Cornerstone Pharmaceuticals
  • CTI BioPharma
  • Eli Lilly
  • Gamida Cell
  • GlaxoSmithKline
  • KaloBios Pharmaceuticals
  • Kiadis Pharma
  • Mirati Therapeutics
  • Onconova Therapeutics
  • Strategia Therapeutics
  • Sumitomo Dainippon Pharma
  • Sunesis Pharmaceuticals
  • Targazyme
  • TetraLogic Pharmaceuticals
Market driver
  • Rise in aging population
  • For a full, detailed list, view our report
Market challenge
  • Use of off-label drugs
  • For a full, detailed list, view our report
Market trend
  • Rise in public awareness
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Myelodysplastic Syndrome Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Myelodysplastic Syndrome Market: Celgene, Novartis and Otsuka

Other Prominent Vendors in the market are: Acceleron Pharma, Amgen, Astellas, Astex , Actinium Pharmaceuticals, Bellicum Pharmaceuticals, BioLineRx, Celator Pharmaceuticals, Cornerstone Pharmaceuticals, CTI BioPharma, Eli-lilly, Gamida Cell , GlaxoSmithKline, KaloBios Pharmaceuticals, Kiadis Pharma, Mirati Therapeutics, Onconova Therapeutics, Strategia Therapeutics, Sumitomo Dainippon Pharma , Sunesis Pharmaceuticals, Targazyme, and TetraLogic Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “Government organizations and pharmaceutical companies are conducting awareness programs to spread knowledge about the disease and associated drugs. In addition, they are also providing patient assistance programs to give low-income people with myelodysplastic syndrome access to these drugs. These two factors will surge the number of people availing treatment services, increasing the sales and consumption of drugs.”

According to the report, the immune system of an individual deteriorates as aging progresses. For this reason, people aged 60 and above are more susceptible to this disease. A surge in the population of this age group will increase the need for treatment drugs, positively influencing the latter's sales and revenue.

Further, the report states that the high cost of drugs used for treating myelodysplastic syndrome can deter people from consuming them.

Companies Mentioned

Celgene, Novartis, Otsuka, Acceleron Pharma, Amgen, Astellas, Astex , Actinium Pharmaceuticals, Bellicum Pharmaceuticals, BioLineRx, Celator Pharmaceuticals, Cornerstone Pharmaceuticals, CTI BioPharma, Eli-lilly, Gamida Cell , GlaxoSmithKline, KaloBios Pharmaceuticals, Kiadis Pharma, Mirati Therapeutics, Onconova Therapeutics, Strategia Therapeutics, Sumitomo Dainippon Pharma , Sunesis Pharmaceuticals, Targazyme, TetraLogic Pharmaceuticals.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Product profile
    • REVLIMID
    • VIDAZA
    • Dacogen
    • Glivec/Gleevec
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Disease overview
    • Understanding the disease
    • Risk factors
      • Table Myelodysplastic syndrome: Risk factors
    • Signs and symptoms
      • Table Myelodysplastic syndrome: Signs and symptoms
    • Pathophysiology
    • Types
      • Table History of myelodysplastic syndrome classification system
      • Table FAB classification system: Types of myelodysplastic syndrome
      • Table WHO classification system: Types of myelodysplastic syndrome
      • Table IPSS classification: Factors and score
      • Table IPSS-R classification: Cytogenetic score
      • Table IPSS-R classification: Score values
      • Table IPSS-R classification: Risk categories and scores
    • Diagnosis
      • Table Diagnostic tests for myelodysplastic syndrome
    • Epidemiology
      • Table Myelodysplastic syndrome: Global incidence based on age 2007-2011 (years)
      • Table Myelodysplastic syndrome: Incidence in US by race 2007-2011
    • Treatment
      • Table Treatment options for myelodysplastic syndrome
      • Table Chemotherapeutic agents
      • Table Immunotherapy drugs
      • Table Supportive therapy for myelodysplastic syndrome
      • Table Drugs that received orphan designation for treatment of myelodysplastic syndrome
  • Pipeline portfolio
    • Table Myelodysplastic syndrome: Drug pipeline
    • Information on pipeline candidates
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global myelodysplastic syndrome market ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Table Global myelodysplastic syndrome market segmentation by drug class
    • Alkylating agents
    • Cytotoxic antibiotics
    • Topoisomerase inhibitors
    • Others
  • Market segmentation by route of administration
    • Table Global myelodysplastic syndrome market segmentation by route of administration
    • Oral
    • Parenteral
  • Geographical Segmentation
    • Table Global myelodysplastic syndrome market segmentation by geography 2014
    • Table Myelodysplastic syndrome market in Americas 2014-2019 ($ millions)
    • Myelodysplastic syndrome market in EMEA
      • Table Myelodysplastic syndrome market in EMEA 2014-2019 ($ millions)
    • Myelodysplastic syndrome market in APAC
      • Table Myelodysplastic syndrome market in APAC 2014-2019 ($ millions)
      • Table Global myelodysplastic syndrome market segmentation by geography 2014-2019 ($ millions)
  • Market drivers
    • Rise in aging population
    • Unmet medical needs
    • Use of diagnostic tools
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Use of off-label drugs
    • Adverse effects of drugs
    • High cost of drugs
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Rise in public awareness
    • Patient assistance programs
    • Increase in R&D
    • Intense competition
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2014
      • Table Ranking of leading companies
      • Table Celgene: YoY growth and revenue of VIDAZA 2012-2014 ($ millions)
      • Table Celgene: YoY growth and revenue of REVLIMID 2012-2014 ($ billions)
      • Table Celgene: Key takeaways
      • Table Otsuka Holdings: Key takeaways
      • Table Novartis: Key takeaways
    • Other prominent vendors
  • Key vendor analysis
    • Celgene
      • Table Celgene: Product segmentation by revenue 2014
      • Table Celgene: Product segmentation by revenue 2013 and 2014
      • Table Celgene: Geographical segmentation by revenue 2014
    • Novartis
      • Table Novartis: Business segmentation by revenue 2014
      • Table Novartis: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Novartis: Geographical segmentation by revenue 2014
    • Otsuka Holdings
      • Table Otsuka Holdings: Business segmentation by revenue 2014
      • Table Otsuka Holdings: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Otsuka Holdings: Geographical segmentation by revenue 2014
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report